Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Articles

Catch up on coverage from the third day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee. 

Day 3 Recap: Maui Derm NP+PA Fall 2024

From dupilumab to OX40s, Zirwas talked about the niche to all atopic dermatitis therapies to make the best decision with your patient.

Picking the Perfect Atopic Dermatitis Therapy with Matthew Zirwas, MD

In a session at Maui Derm NP+PA Fall, Zirwas talked about the newfound discoveries of causation within the AD space. 

Scientific Advancements in Atopic Dermatitis with Matthew Zirwas, MD

Allie Karas is the vice president of content for the Health Care Specialty Group division of MJH Life Sciences. She attended Rider University and earned a degree in journalism before pursing a masters in magazine writing from New York University. Prior to making a switch to health care news in 2018, Allie spent 6 years in New York City working in political journalism. She enjoys spending time with her husband and 3 kids, cooking, working out, and her dog Bo. Follow her on Twitter at 

In his signature Maui Derm NP+PA Fall 2024 session, Shapiro discusses the importance of acting quickly when confronted with a patient who has scarring alopecia.

Jerry Shapiro, MD: Advances in Hair Loss Management and Treatment

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

View

News 

New Orleans - Determining the relative risk of a cutaneous drug reaction pattern is vital to determining whether the drug(s) in question can be continued currently or rechallenged in the future,

Risk levels differentiate drug reactions